Evidence map›Paper›PMID 31481080›Full record

ArticleJournal of nanobiotechnology2019

Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy.

Chunai Gong, Jing Tian, Zhuo Wang, Yuan Gao, Xin Wu, Xueying Ding, Lei Qiang, Guorui Li, Zhimin Han, Yongfang Yuan and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 3 pooled it
12.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 3 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Current trends in exosomes as therapeutic drug delivery systems.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Chunai GongDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Jing TianDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Zhuo WangDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Yuan GaoDepartment of Clinical Pharmacy and Pharmaceutical Management, School of Pharmacy, Fudan University, Shanghai, 201203, People's Republic of China.
Xin WuDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Xueying DingDepartment of Clinical Pharmacy, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200080, People's Republic of China.
Lei QiangDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Guorui LiDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Zhimin HanDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China.
Yongfang YuanDepartment of Pharmacy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, People's Republic of China. nmxyyf@126.com.
Shen GaoDepartment of Pharmaceutics, Changhai Hospital, Second Military Medical University, Shanghai, 200433, People's Republic of China. liullk@126.com.ORCID http://orcid.org/0000-0002-5125-1606
Second Military Medical University · CNShanghai Jiao Tong University · CNFudan University · CN

Funding

Basic Research Projects of Shanghai Science and Technology Commission 18JC1414200Clinical Pharmacy Innovation Research Institute of Shanghai Jiao Tong University School of Medicine CXYJY2019MS002National Natural Science Foundation of China 81672516National Natural Science Foundation of China 81672545National Natural Science Foundation of China 81772749National Natural Science Foundation of China 81903141Shanghai Municipal Commission of Health and Family Planning-Construction of clinical pharmacy service system 2016ZB0303
6 · The paper itself

Abstract

Exosomes (Exo) hold great promise as endogenous nanocarriers that can deliver biological information between cells. However, Exo are limited in terms of their abilities to target specific recipient cell types. We developed a strategy to isolate Exo exhibiting increased binding to integrin α

Indexed as

AnimalsCell Line, TumorDoxorubicinDrug Delivery SystemsExosomesFemaleGene Expression Regulation, NeoplasticHumansHydrophobic and Hydrophilic InteractionsMCF-7 CellsMiceMicroRNAsTHP-1 CellsTriple Negative Breast NeoplasmsDoxorubicinMicroRNAsCo-deliveryDoxorubicinExosomeMicroRNA 159Triple-negative breast cancer

Identifiers

PMID31481080
PMCPMC6721253
OpenAlexW2971629072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.